HPB & Spleen · 12 November 2023

Optimal Timing for Pancreatic Cancer Adjuvant Therapy: A Survival Analysis

Delving into the ideal moment for post-pancreatic adenocarcinoma surgery chemotherapy, a simulated trial tracked 1491 patients. Noteworthy findings revealed a median survival of 29.9 months for late initiators (>4-8 weeks) versus 30.4 months for early starters (0-4 weeks). Encouragingly, delaying treatment up to 8 weeks post-surgery showed comparable safety, offering a nuanced approach that respects recovery timelines and enhances adjuvant therapy accessibility.

Journal Article by Kirkegård J, Ladekarl M, Lund A and Mortensen F in Ann Surg Oncol

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Ann Surg Oncol2 Nov 2026

Pancreatic ductoscopy guides tissue preservation

In two older patients having robotic surgery for a pancreatic growth, ductoscopy and checks of the cut edge let surgeons leave the remaining pancreas in place.

HPB & Spleen30 Oct 2026

Intrahepatic cholangiocarcinoma has more options

Resection remains central, but care now includes preoperative therapy, liver-directed treatments and drugs matched to tumor changes.

Ann Surg Oncol29 Oct 2026

Pancreatic cancer: longer survival with combined treatment

For locally advanced pancreatic cancer, cryoablation plus drug treatment was linked to longer median survival than drug treatment alone, but the result does not prove benefit.

All papers in HPB & Spleen →